D
Deleted member 473
Single dose of Pfizer-Biontech vaccine may not protect elderly from Covid-19 infection
A significant proportion of people over 80 may have only a “poor” immune response after a single dose of the Pfizer-Biontech vaccine, researchers have said.Thre
www.thetimes.co.uk
Pfizer BioNTech vaccine likely to be effective against B1.1.7 strain of SARS-CoV-2
The Pfizer BioNTech vaccine BNT162b2 is likely to be effective against the B1.1.7 variant of SARS-CoV-2, even though its efficacy is modestly affected, say
www.cam.ac.uk
The seven individuals who were unable to neutralise the virus after the first dose (of Pfizer) were all aged over 80 years old. This accounts for almost half of the 15 individuals in this age group. However, at a follow-up visit after these individuals had received their second dose (given at three weeks), they were all able to neutralise the virus.
Last edited by a moderator: